The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Chernousov P.A.

Sechenov First Moscow Medical University (Sechenov University)

Vekhova K.A.

Sechenov First Moscow Medical University (Sechenov University)

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Cognitive impairment in patients with arterial hypertension

Authors:

Zaharov V.V., Chernousov P.A., Vekhova K.A., Bogolepova A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4‑2): 41‑48

DOI: 10.17116/jnevro202412404241

Read: 1738 times

Download PDF (RU)
Contact the author
Table of contents

COGNITIVE IMPAIRMENT IN PATIENTS WITH ARTERIAL HYPERTENSION
COGNITIVE IMPAIRMENT IN PATIENTS WITH ARTERIAL HYPERTENSION

To cite this article:

Zaharov VV, Chernousov PA, Vekhova KA, Bogolepova AN. Cognitive impairment in patients with arterial hypertension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4‑2):41‑48. (In Russ.)
https://doi.org/10.17116/jnevro202412404241

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Indi­cators of cognitive impairment of varying seve­rity in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):14-20
Possibilities of mirror therapy in cognitive reha­bilitation after stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):64-71
Possibilities of physiotherapy in glaucomatous optic neuropathy after glaucoma surgery. Russian Annals of Ophthalmology. 2024;(3):88-94
Asso­ciation between previous appe­ndectomy and cognitive impairment in adults: a case-control study. Piro­gov Russian Journal of Surgery. 2024;(7):73-77
Impact of meta­bolic para­meters and risk factors on surfactant proteins SP-A and SP-D in abdo­minal obesity. Russian Journal of Preventive Medi­cine. 2024;(7):60-66
Features of cognitive impairment in bipo­lar affe­ctive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19
Cognitive impairments and emotional diso­rders and their correction in peri­menopausal women. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):48-53
Inte­grative asse­ssment of the effe­ctiveness and safety of outpatient use of Pica­milon. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):119-130
Possibilities of using cyto­protectors in complex therapy of chro­nic coro­nary heart disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):410-419
Clinical and meta­bolic features of neurocognitive testing in children and adolescents with type 1 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(8):60-65

Arterial hypertension (AH) is a leading risk factor for cardiovascular diseases including cerebrovascular complications. Strokes and/or vascular cognitive impairment (VCI) are considered as a clinical sign of brain damage as a target organ in hypertension. To identify and assess the severity of VCI, patients with hypertension should undergo a neuropsychological assessment. Neuroimaging confirm the vascular origin of cognitive impairment. Patient management should include antihypertensive therapy along with neuroprotection. Among different neuroprotective therapy, ethylmethylhydroxypyridine succinate (mexidol) is one of medication with serious evidence of clinical efficacy.

Keywords:

arterial hypertension
cognitive impairment
cerebral vascular disease
neuroprotection
ethylmethylhydroxypyridine succinate
mexidol

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Chernousov P.A.

Sechenov First Moscow Medical University (Sechenov University)

Vekhova K.A.

Sechenov First Moscow Medical University (Sechenov University)

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Received:

15.02.2024

Accepted:

16.02.2024

List of references:

  1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  2. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25—64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.). https://doi.org/10.15829/1728-8800-2014-4-4-14
  3. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
  4. Zakharov VV, Vakhnina NV, Parfenov VA. Cognitive disorders and their treatment in hypertension. Meditsinskiy sovet = Medical Council. 2017;(1S):6-12. (In Russ.). https://doi.org/10.21518/2079-701X-2017-0-6-12
  5. Starchina YuA, Zakharov VV. Cognitive impairment in hypertension. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):113-118. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-113-118
  6. Meissner A. Hypertension and the Brain: A Risk Factor for More Than Heart Disease. Cerebrovasc Dis. 2016;42(3-4):255-262.  https://doi.org/10.1159/000446082
  7. Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertension. Circ Res. 2019;124(7):1025-1044. https://doi.org/10.1161/CIRCRESAHA.118.313260
  8. Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016;36:1653-1667. https://doi.org/10.1177/0271678X16662891
  9. Zhetishev RR, Kamchatnov PR, Mikhailova NA, Ivashchenko AR. Prevalence and risk factors of asymptomatic cerebral infarction. The Clinician. 2015;9(1):13-17. (In Russ.). https://doi.org/10.17650/1818-8338-2015-1-13-17
  10. Lei C, Deng Q, Li H, Zhong L. Association Between Silent Brain Infarcts and Cognitive Function: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2019;28(9):2376-2387. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.036
  11. Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology. 2010;75(24):2221-2228. https://doi.org/10.1212/WNL.0b013e3182020349
  12. Schmidt R, Schmidt H, Haybaeck J, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol. 2011;122(2):171-185.  https://doi.org/10.1007/s00401-011-0851-x
  13. Smith EE, O’Donnell M, Dagenais G, et al. PURE Investigators. Early cerebral small vessel disease and brain volume, cognition and gait. Ann Neurol. 2015;77(2):251-261.  https://doi.org/10.1002/ana.24320
  14. Basile AM, Pantoni L, Pracucci G, et al. LADIS Study Group. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis. 2006;21(5-6):315-322.  https://doi.org/10.1159/000091536
  15. Wardlaw JM, Makin SJ, Valdés Hernández MC, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimers Dement. 2017;13(6):634-643.  https://doi.org/10.1016/j.jalz.2016.09.006
  16. LADIS Study Group. 2001—2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis. 2011;32(6):577-588.  https://doi.org/10.1159/000334498
  17. Jahno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in discirculatory encephalopathy. Message 2: cognitive impairment. Nevrologicheskij Zhurnal. 2001;6(3):10. (In Russ.).
  18. Ostroumova TM, Parfenov VA, Ostroumova OD. Cognitive impairment in patients with arterial hypertension: a relationship with the level and daily blood pressure profile and pathogenetic mechanisms. Rational Pharmacotherapy in Cardiology. 2019;15(2):258-264. (In Russ.). https://doi.org/10.20996/1819-6446-2019-15-2-258-264
  19. Hughes TM, Sink KM. Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. Am J Hypertens. 2016;29(2):149-157.  https://doi.org/10.1093/ajh/hpv180
  20. Langbaum JB, Chen K, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012; 33:827.e11-827.e19  https://doi.org/10.1016/j.neurobiolaging.2011.06.020
  21. Kim T, Yi D, Byun MS, et al. KBASE Research Group. Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology. Alzheimers Res Ther. 2022;14(1):193.  https://doi.org/10.1186/s13195-022-01149-7
  22. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study. JAMA. 1997;277(10):813-817.  https://doi.org/10.1001/jama.1997.03540340047031
  23. Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
  24. Zueva IB. Hypertension and cognitive impairments: Possible mechanisms of development, diagnosis, and approaches to therapy. Terapevticheskii Arkhiv. 2015;87(12):96-100. (In Russ.). https://doi.org/10.17116/terarkh2015871296-100
  25. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55.  https://doi.org/10.1016/s0197-4580(00)00096-8
  26. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451. https://doi.org/10.1136/bmj.322.7300.1447
  27. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145. https://doi.org/10.1016/s0140-6736(96)90608-x
  28. Starchina YuA, Sleptcova KS. Treatment of cognitive impairment in arterial hypertension. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):90-95. (In Russ.). https://doi.org/10.14412/2074-2711-2021-5-90-95
  29. Elias MF, Wolf PA, D’Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353-364.  https://doi.org/10.1093/oxfordjournals.aje.a116868
  30. Kim H, Ang TFA, Thomas RJ, et al. Long-term blood pressure patterns in midlife and dementia in later life: Findings from the Framingham Heart Study. Alzheimers Dement. 2023;19(10):4357-4366. https://doi.org/10.1002/alz.13356
  31. Sachdev P, Kalaria R, O’Brien J, et al. Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218.  https://doi.org/10.1097/WAD.0000000000000034
  32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
  33. Vakhnina NV. Cognitive disorders and therapy in patients with hypertension. Meditsinskiy sovet = Medical Council. 2014;(5):30-37. (In Russ.).
  34. Román GC, Erkinjuntti T, Wallin A, et al. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1(7):426-436.  https://doi.org/10.1016/s1474-4422(02)00190-4
  35. Fladd D. Subcortical vascular dementia. Geriatr Nurs. 2005;26(2):117-121.  https://doi.org/10.1016/j.gerinurse.2005.01.001
  36. Erkinjuntti T. Subcortical vascular dementia. Cerebrovasc Dis. 2002;13(suppl 2):58-60.  https://doi.org/10.1159/000049152
  37. Menon U, Kelley RE. Subcortical ischemic cerebrovascular dementia. Int Rev Neurobiol. 2009;84:21-33.  https://doi.org/10.1016/S0074-7742(09)00402-4
  38. Preobrazhenskaya IS, Yakhno NN. Vascular cognitive impairment — clinical manifestations, diagnostic approaches and treatment. Nevrologicheskii zhurnal. 2007;12(5):45-50. (In Russ.).
  39. Zakharov VV. Povedencheskaya nevrologiya. M.: Profmedpress; 2022. (In Russ.).
  40. Cristofori I, Cohen-Zimerman S, Grafman J. Executive functions. Handb Clin Neurol. 2019;163:197-219.  https://doi.org/10.1016/B978-0-12-804281-6.00011-2
  41. Zaharov VV, Vahnina NV. Cognitive disorders in arterial hypertension. Nervnye bolezni. 2013;3:16-21. (In Russ.).
  42. Yakhno NN, Zakharov VV, Lokshina AB. The syndrome of moderate cognitive disorders in dyscirculatory encephalopathy. Zhurnal Neurologii i Psychiatrii im. S.S. Korsakova. 2005;105(2):13-17. (In Russ.).
  43. Xie C, Zhong D, Zhang Y, et al. Prevalence and risk factors of cognitive impairment in Chinese patients with hypertension: a systematic review and meta-analysis. Front Neurol. 2024;14:1271437.
  44. Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in dyscirculatory encephalopathy. Message 1: Motor disorders. Nevrologicheskij zhurnal. 2001;6(2):10-16. (In Russ.).
  45. Bryzhakhina VG, Damulin IV. Statolocomotor disorders in elderly patients with dyscirculatory encephalopathy and dementia. Bulletin of practical neurology. 2003;7:17-21. (In Russ.).
  46. Bryzhakhina VG, Damulin IV, Yakhno NN. Disturbances in walking and balance in dyscirculatory encephalopathy. Post 1. Neurological Journal. 2004;9:(2):11-16. (In Russ.).
  47. Damulin IV, Bryzakhina VG, Shashkova EV, Yakhno NN. Disturbances in walking and balance in dyscirculatory encephalopathy. Message 2. Clinical, morphological and MRI comparisons. Neurological Journal. 2004;9(4):13-18. (In Russ.).
  48. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for 248 dementia: Validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451-1454. https://doi.org/10.1046/j.1532-5415.2003.51465.x
  49. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975;12(3):189-198.  https://doi.org/10.1016/0022-3956(75)90026-6
  50. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x
  51. Zakharov VV, Voznesenskaya TG. Nervno-psikhicheskie narusheniya: diagnosticheskie testy. M.: MEDpress; 2013. (In Russ.).
  52. Zakharov VV, Vakhnina NV, Gromova DO, et al. The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):83-91. (In Russ.). https://doi.org/10.14412/2074-2711-2015-4-83-91
  53. Martynov AI, Tanashyan MM, Malyavin AG, et al. Resolution of the Council of Experts «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive impairment». Therapy. 2023;9(10):148-158. (In Russ.). https://doi.org/10.18565/therapy.2023.10.148—158
  54. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023;22(7):602-618.  https://doi.org/10.1016/S1474-4422(23)00131-X
  55. Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology. 2009;72(20):1727-1734. https://doi.org/10.1212/01.wnl.0000345062.86148.3f
  56. Ostroumova OD, Parfenov VA, Ostroumova TM, et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5-12. (In Russ.). https://doi.org/10.26442/2075082X.2021.1.200575
  57. Iadecola C, Yaffe K, Biller J, et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):e67-e94.  https://doi.org/10.1161/HYP.0000000000000053
  58. Piradov MA, Tanashyan MM, Domashenko MA. Neuroprotection in cerebrovascular diseases: the search for life on Mars or a promising direction of treatment. Part 1. Acute disorders of cerebral circulation. Annaly klinicheskoi i eksperimental’noi nevrologii. 2015;9(1):41-50. (In Russ.).
  59. Piradov MA, Tanashyan MM, Domashenko MA, Maksimova MYu. Neuroprotection in cerebrovascular diseases: the search for life on Mars or a promising direction of treatment. Part 2. Chronic forms of cerebral circulation disorders. Annaly Klinicheskoi i Eksperimental’noi Nevrologii. 2015;9(3):10-19. (In Russ.).
  60. Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
  61. Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
  62. Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159. (In Russ.). https://doi.org/10.18565/therapy.2023.1.145-159

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.